American Society of Clinical Oncology

Ruben Mesa, MD: Ruxolitinib as a Myelofibrosis Treatment

June 07, 2019

Article

Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses treating myelofibrosis with ruxolitinib therapy.

Ruben Mesa, MD: Myelofibrosis Patients Frequently Present Symptoms

June 07, 2019

Article

Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the visible symptoms and diagnosis process for patients with myelofibrosis.

Naveen Pemmaraju, MD: Tagraxofusp for BPDCN

June 06, 2019

Article

New trial results show the cytotoxin delivers clinical responses in patients with untreated or relapsed forms of the rare disease.

Naveen Pemmaraju, MD: Managing Anemia with Ruxolitinib Care

June 05, 2019

Article

The common, concerning adverse effect requires a careful eye from clinicians and new therapy options.

New Therapy on Horizon for Rare Lung Cancer Subtype

June 04, 2019

Article

MET inhibitor capmatinib may hold promise for a small subtype of patients with a non-small cell lung cancer, according to new ASCO 2019 findings.

Naveen Pammaraju, MD: Primary Care & JAK1 Inhibitors in Myelofibrosis

June 04, 2019

Article

Patients with the rare cancer condition requires both a collaborative physician network and proven therapies.

Investigational Isatuximab Shows Added Benefit for Multiple Myeloma

June 03, 2019

Article

New phase 3 trial results show the monoclonal antibody plus pomalidomide and dexamethasone improves progression free survival and overall response rate among patients with RRMM.

New Immunotherapy Blocks Key Macrophage Checkpoint in AML Care

June 03, 2019

Article

Hu5F9-G4, aided by azacytidine, showed the potential to remove signals on cancer cells that would normally prevent a patient’s body from eliminating said cells.

Subcutaneous Daratumumab Non-Inferior, Less Burdensome than IV Regimen

June 03, 2019

Article

Phase 3 results show the therapy plus recombinant human hyaluronidase is comparably safe and effective for patients with relapsed-refractory multiple myeloma.

Primary Care Physicians Hold Significant Value in Oncology Care

June 03, 2019

Article

A discussion held at ASCO 2019 highlighted the statistical value associated with primary care collaboration across specialties.

x